by Medscape
Listen to Medscape InDiscussion: Schizophrenia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Language
🇺🇲
Publishing Since
8/2/2022
Email Addresses
1 available
Phone Numbers
0 available
July 20, 2023
<p>Drs John M. Kane and Mitchell Arnovitz discuss assessment of patients for negative symptoms of schizophrenia and the potential of MDMA in alleviating these symptoms in supervised treatment settings.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984490). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Schizophrenia https://emedicine.medscape.com/article/288259-overview</p> <p>MDMA for the Treatment of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/35743326/</p> <p>MDMA (Ecstasy/Molly) https://nida.nih.gov/publications/drugfacts/mdma-ecstasymolly</p> <p>The NIMH-MATRICS Consensus Statement on Negative Symptoms https://pubmed.ncbi.nlm.nih.gov/16481659/</p> <p>The Current Conceptualization of Negative Symptoms in Schizophrenia https://pubmed.ncbi.nlm.nih.gov/28127915/</p> <p>Akinesia https://www.ncbi.nlm.nih.gov/books/NBK562177/</p> <p>An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) Commonly Used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS) https://pubmed.ncbi.nlm.nih.gov/29430333/</p> <p>Ecological Momentary Assessment https://pubmed.ncbi.nlm.nih.gov/18509902/</p> <p>Schizophrenia Medication https://emedicine.medscape.com/article/288259-medication#2</p> <p>Cariprazine, a Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety https://pubmed.ncbi.nlm.nih.gov/34091867/</p> <p>DRD3 Dopamine Receptor D3 [<em>Homo sapiens</em> (human)] https://www.ncbi.nlm.nih.gov/gene/1814</p> <p>MDA https://dictionary.apa.org/mda</p> <p>Transcranial Magnetic Stimulation: A Review of Its Evolution and Current Applications https://pubmed.ncbi.nlm.nih.gov/31359968/</p> <p>Memantine https://www.ncbi.nlm.nih.gov/books/NBK500025/</p> <p>Making MDMA a Medicine (II) (Re)scheduling for Schedule I Substances https://maps.org/news/bulletin/making-mdma-a-medicine-ii-rescheduling-for-schedule-1-substances/</p> <p>Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK548187/</p> <p>Metaplasticity: Tuning Synapses and Networks for Plasticity https://pubmed.ncbi.nlm.nih.gov/18401345/</p> <p>MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/34708874/</p> <p>Reduction in Social Anxiety After MDMA-Assisted Psychotherapy With Autistic Adults: A Randomized, Double-Blind, Placebo-Controlled Pilot Study https://pubmed.ncbi.nlm.nih.gov/30196397/</p> <p>Prefrontal Cortex-Nucleus Accumbens Interaction: In Vivo Modulation by Dopamine and Glutamate in the Prefrontal Cortex https://pubmed.ncbi.nlm.nih.gov/18508116/</p> <p>Serotonin Syndrome https://emedicine.medscape.com/article/2500075-overview</p>
June 21, 2023
<p>Drs John M. Kane and Delbert G. Robinson discuss psychoeducation, treatment options, and possible side effects of medication for patients experiencing their first episode of schizophrenia.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984489). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Schizophrenia https://emedicine.medscape.com/article/288259-overview</p> <p>First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/21141653/</p> <p>Comprehensive Versus Usual Community Care for First Episode Psychosis: Two-Year Outcomes From the NIMH RAISE Early Treatment Program https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981493/</p> <p>Schizophrenia Treatment & Management https://emedicine.medscape.com/article/288259-treatment#d9</p> <p>Akinesia https://pubmed.ncbi.nlm.nih.gov/32965848/</p> <p>Clozapine (Rx) https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972</p> <p>20-year Nationwide Follow-up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/29621900/</p> <p>A Randomized, Controlled Trial of Omega-3 Fatty Acids Plus an Antioxidant for Relapse Prevention After Antipsychotic Discontinuation in First-Episode Schizophrenia https://pubmed.ncbi.nlm.nih.gov/24996507/</p> <p>Beneficial Effects of Omega-3 Fatty Acid Supplementation in Schizophrenia: Possible Mechanisms https://pubmed.ncbi.nlm.nih.gov/32620164/</p> <p>An Overview of Coordinated Specialty Care (CSC) for Persons With First Episode Psychosis https://www.nasmhpd.org/content/presentation/overview-coordinated-specialty-care-csc-persons-first-episode-psychosis</p>
May 23, 2023
<p>Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis.</p> <p>Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984484). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.</p> <p><strong>Resources</strong></p> <p>Schizophrenia https://emedicine.medscape.com/article/288259-overview</p> <p>Schizophrenia and Clinical High Risk https://www.ampscz.org/about/schizophrenia-chr/</p> <p>PRIME Psychosis Prodrome Research Clinic https://medicine.yale.edu/psychiatry/research/programs/clinical_people/prodome/?locationId=460</p> <p>Conversion to Psychosis in Adolescents and Adults: Similar Proportions, Different Predictors https://pubmed.ncbi.nlm.nih.gov/32248862/</p> <p>Clinical Validity of DSM-5 Attenuated Psychosis Syndrome: Advances in Diagnosis, Prognosis, and Treatment https://pubmed.ncbi.nlm.nih.gov/31746950/</p> <p>Prevalence of Individuals at Clinical High-risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/34827543/</p> <p>Stability of Mental Disorder Prevalence Estimates Among School-aged Children and Adolescents: Findings From the Community-based Project to Learn About Youth-mental Health (PLAY-MH) and Replication-PLAY-MH (Re-PLAY-MH), 2014-2017 https://pubmed.ncbi.nlm.nih.gov/35661706/</p> <p>The Clinician's Illusion https://pubmed.ncbi.nlm.nih.gov/6334503/</p> <p>What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors https://pubmed.ncbi.nlm.nih.gov/31219164/</p> <p>Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/27806157/</p> <p>Accelerated Cortical Thinning Precedes and Predicts Conversion to Psychosis: The NAPLS3 Longitudinal Study of Youth at Clinical High-risk https://pubmed.ncbi.nlm.nih.gov/36434057/</p> <p>Treatment Outcomes for Young People at Clinical High Risk for Psychosis: Data From a Specialized Clinic https://pubmed.ncbi.nlm.nih.gov/34309198/</p> <p>Real-world Effectiveness of Antipsychotic Treatment in Psychosis Prevention in a 3-year Cohort of 517 Individuals at Clinical High Risk From the SHARP (ShangHai at Risk for Psychosis) https://pubmed.ncbi.nlm.nih.gov/32436725/</p> <p>The PRIME North America Randomized Double-blind Clinical Trial of Olanzapine Versus Placebo in Patients at Risk of Being Prodromally Symptomatic for Psychosis: I. Study Rationale and Design https://pubmed.ncbi.nlm.nih.gov/12648731/</p> <p>Accelerating Medicines Partnership® Program - Schizophrenia (AMP® SCZ) https://www.nimh.nih.gov/research/research-funded-by-nimh/research-initiatives/accelerating-medicines-partnershipr-program-schizophrenia-ampr-scz#:~:text=The%20Accelerating%20Medicines%20Partnership%C2%AE,multiple%20public%20and%20private%20organizations.</p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
